FGL vs BNP (B-type Natriuretic Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
FGL
FGL (FG Loop) is a synthetic peptide that mimics the neural cell adhesion molecule (NCAM) FG loop region. It promotes neuroplasticity and has shown cognitive-enhancing effects in research.
Full details →BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →Side-by-Side Comparison
| Aspect | FGL | BNP (B-type Natriuretic Peptide) |
|---|---|---|
| Mechanism | Binds to FGFR1 (fibroblast growth factor receptor 1) to activate downstream signaling cascades that promote neurite outgrowth, synaptic plasticity, and neuronal survival. | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. |
| Typical Dosage | Research protocols have used subcutaneous doses ranging from 1-10mg. Intranasal administration also studied. Optimal dosing not established. | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. |
| Administration | Subcutaneous injection or intranasal administration. Research compound with limited human dosing data. | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. |
| Side Effects | Limited human data available. Animal studies show good tolerability. | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. |
| Best For |